Regulatory Document Accuracy is crucial for maintaining compliance and minimizing legal risks.
High accuracy rates directly influence operational efficiency and financial health, enabling organizations to avoid costly penalties.
This KPI serves as a leading indicator for overall business performance, as inaccuracies can lead to significant delays in project timelines and resource allocation.
By tracking results in this area, companies can ensure they meet industry standards and improve their strategic alignment.
Effective management reporting on this metric helps drive data-driven decision-making, ultimately enhancing ROI and forecasting accuracy.
High values indicate a robust compliance framework and effective document management processes. Conversely, low accuracy can signal systemic issues, such as inadequate training or poor data entry practices. Ideal targets typically hover around 98% accuracy or higher.
We have 12 relevant benchmarks in our benchmarks database.
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | average rejection rate | Aug. 15, 2021 to Apr. 15, 2022. | CDER submissions with study data subject to TRC validations. | pharmaceutical regulatory submissions. | United States. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | average | Prior years average and Calendar Year 2018. | All CDER submissions with study data. | pharmaceutical regulatory submissions. | United States. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | Calendar Year 2018. | All CDER submissions with study data (NDA, ANDA, BLA, commer | pharmaceutical regulatory submissions. | United States. | 2,895 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | Calendar Year 2018. | Commercial IND submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 649 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | Calendar Year 2018. | BLA submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 291 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | Calendar Year 2018. | ANDA submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 1,078 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | Calendar Year 2018. | NDA submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 877 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | 12/18/2016 to 3/31/2018 and 12/18/2017 to 3/31/2018 analysis | All CDER submissions with study data (NDA, ANDA, BLA, commer | pharmaceutical regulatory submissions. | United States. | 3,221 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | 12/18/2017 to 3/31/2018 analysis window. | Commercial IND submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 176 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | 12/18/2016 to 3/31/2018 analysis window. | BLA submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 473 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | 12/18/2016 to 3/31/2018 analysis window. | ANDA submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 1,446 submissions with study data. |
Source: Subscribers only
Source Excerpt: Subscribers only
Formula: Subscribers only
Additional Comments: Subscribers only
| Value | Unit | Type | Company Size | Time Period | Population | Industry | Geography | Sample Size |
| Subscribers only | percent | failure rate | 12/18/2016 to 3/31/2018 analysis window. | NDA submissions with study data to CDER. | pharmaceutical regulatory submissions. | United States. | 1,126 submissions with study data. |
Many organizations overlook the importance of regular audits, which can lead to unnoticed inaccuracies in regulatory documents.
Enhancing regulatory document accuracy requires a multifaceted approach focused on process optimization and employee engagement.
A leading financial services firm faced challenges with regulatory document accuracy, which had dropped to 85%. This situation jeopardized compliance and threatened to incur hefty fines. To address this, the firm initiated a comprehensive program called “Accuracy First,” spearheaded by the Chief Compliance Officer. The program focused on enhancing training, implementing a new document management system, and automating data entry processes.
Within 6 months, the accuracy rate improved to 97%. The new system provided real-time updates and version control, significantly reducing discrepancies. Staff training sessions emphasized the importance of compliance, leading to heightened awareness and accountability among employees.
The firm also established a quarterly review process to assess document accuracy and compliance. This proactive approach ensured that any emerging issues were addressed promptly, fostering a culture of continuous improvement.
As a result, the firm not only avoided potential penalties but also enhanced its reputation in the market. The “Accuracy First” initiative transformed compliance from a back-office function into a strategic asset, aligning with the firm’s long-term goals and operational efficiency.
This KPI is associated with the following categories and industries in our KPI database:
KPI Depot takes you from KPI intelligence to finished deliverable. Consultants, strategy teams, FP&A leaders, and analytics teams use it to answer the two hardest questions in performance management, what to measure and what the target should be, and then to produce the scorecard itself.
The difference is intelligence, not just data. Anyone can list metrics. Every KPI in KPI Depot carries 13 practical attributes, from formula and measurement approach to diagnostic questions, risk warnings, and Balanced Scorecard perspective, across 15 corporate functions and 153 industries. And every target you set is grounded in our database of 34,304 source-attributed benchmarks, each detailing metric value, company size, time period, industry, geography, sample size, and source. Benchmark data at this scale is otherwise the domain of research services costing thousands to hundreds of thousands of dollars per year.
When your metrics are selected, KPI Depot finishes the job: export an interactive Strategy Map, a Balanced Scorecard with formulas and tracking columns, or a CSV KPI pack, and go from research to working deliverable in hours instead of weeks.
Formerly the Flevy KPI Library, KPI Depot is trusted by teams at organizations including Accenture, EY, IBM, PepsiCo, Samsung, and Vodafone.
Got a question? Email us at [email protected].
An ideal accuracy rate typically hovers around 98% or higher. This threshold ensures compliance and minimizes the risk of penalties.
Regular audits should occur at least quarterly. Frequent reviews help identify inaccuracies and maintain compliance with evolving regulations.
Employee training is critical for ensuring understanding of compliance standards. Well-informed staff are less likely to make errors in documentation.
Yes, automation significantly reduces human error in data entry and validation. Implementing automated tools enhances operational efficiency and accuracy rates.
Low accuracy can lead to costly penalties and damage to reputation. It may also result in operational inefficiencies and resource misallocation.
Feedback from audits should inform process improvements and training needs. Addressing identified weaknesses proactively enhances overall accuracy.
Each KPI in our knowledge base includes 13 attributes.
A clear explanation of what the KPI measures
The typical business insights we expect to gain through the tracking of this KPI
An outline of the approach or process followed to measure this KPI
The standard formula organizations use to calculate this KPI
Insights into how the KPI tends to evolve over time and what trends could indicate positive or negative performance shifts
Questions to ask to better understand your current position is for the KPI and how it can improve
Practical, actionable tips for improving the KPI, which might involve operational changes, strategic shifts, or tactical actions
Recommended charts or graphs that best represent the trends and patterns around the KPI for more effective reporting and decision-making
Potential risks or warnings signs that could indicate underlying issues that require immediate attention
Suggested tools, technologies, and software that can help in tracking and analyzing the KPI more effectively
How the KPI can be integrated with other business systems and processes for holistic strategic performance management
Explanation of how changes in the KPI can impact other KPIs and what kind of changes can be expected
NEW Mapping to a Balanced Scorecard perspective (financial, customer, internal process, learning & growth)